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Objectives: Many medical and epidemiological research studies are based 
on observational data. In this study, we compare three different propensity 
scores: unadjusted propensity score (UPS), prognostic propensity score 1(PPS1), 
and prognostic propensity score 2(PPS2) using the inverse probability weighted 
(IPW) estimator for assessing patient reported outcomes (PROs) in terms of 
average treatment effect (ATE) and average treatment effect on the treated 
(ATT). MethOds: We conducted a Monte Carlo simulation study to evaluate these 
three propensity scores for estimating ATE and ATT in terms of bias, mean squared 
error (MSE), and coverage probability (CP). Results: The simulation results show 
that PPS1 has the poorest performance compared to UPS and PPS2 in terms of bias, 
MSE and CP. cOnclusiOns: Based on these simulation results, we recommend 
using UPS and PP2 for estimating ATE and ATT for patient reported outcomes in 
practice.
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BaRRieRs in conducting ReseaRch in the field of Radiology: 
PeRcePtions of health caRe PRofessionals fRoM a develoPing nation
Beg M.
The Aga Khan University Hospital, Karachi, Pakistan
Objectives: To identify proportion of radiology Health care professionals’ opinions 
regarding level of difficulty in conducting research in radiology and to ascertain bar-
riers associated in conducting research activities in field of radiology. MethOds: 
Cross-sectional analytical study was conducted during International Conference 
organized by Radiological Society of Pakistan in November 2009 at Sheraton Hotel, 
Karachi. Data were collected using a structured, self-administered questionnaire 
from participants willing to participate in research registered for Annual Radiology 
Research Workshop piloted during conference; via non-probability convenience 
technique. Data were analyzed using SPSS versions 19.0.Means±SD were computed 
for quantitative and proportions calculated for qualitative variables. Chi square 
and Fisher Exact tests applied for categorical variables. A p-value of < 0.001 was 
considered significant. Results: Response rate was 76% (n= 78/103), 65.4% agreed 
that conducting research in the field of radiology is difficult. Most of the participants 
(69.2%) who had not published papers believed that research in radiology is difficult 
as compared to those who had published a paper (30.8%) (p= 0.026). However, age, 
sex, attending conferences and presenting papers did not significantly influence 
response of participants. The top three barriers in conducting research in field of 
radiology were time required to provide clinical services (92.3%), lack of dedicated 
time for research (91.0%) and diminished income in research (88.5%). Although 
similar responses were observed among residents and consultants regarding bar-
riers in conducting research, more residents than consultants believed that lack of 
support from dean (p= 0.037) and diminished income in research activities (p= 0.003) 
were significant barriers. cOnclusiOns: Most of the participants’ opinion was 
that conducting research in field of radiology is difficult. Time required providing 
clinical services, lack of dedicated time for research, diminished income in research 
activities were identified as most important barriers in conducting research. Similar 
responses were observed among residents and consultants regarding barriers in 
conducting research.
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views of health caRe PRovideRs on Medical eRRoRs in KaRachi, 
PaKistan
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Objectives: Incidence of medical errors is an area of concern for health care 
providers and policy makers. The large number of preventable errors, risk of 
litigations, patients’ insecurity and lack of confidence in health care provision 
is a concern globally. In an underdeveloped country like Pakistan, patient safety 
is an important trepidation as it poses a great cost burden on health care sys-
tem. Objectives of this cross-sectional analytical study are, to estimate the rate 
of medical errors and to assess the factors that influence medical error report-
ing in Pakistan. MethOds: Data were collected over period of three months, via 
self-administered survey questionnaire. 385 participants, including doctors, 
nurses and paramedics from different private and government hospitals of 
Karachi were selected by non-probability convenience sampling technique. 
Questionnaire elicited information about number of errors witnessed and 
reported, by health care providers and factors that influence error-reporting, 
after an informed consent. Results: According to the preliminary review of 
data, approximately 90 percent of health care professional believe that medical 
errors are common. More than 50 percent have witnessed medical errors. 80 per-
cent of the population surveyed has experienced a medical error. Approximately 
half of the participants believe that medical errors are not often reported in our 
country. cOnclusiOns: Though a substantial number of the health care profes-
sionals in Karachi have ever witnessed or experienced a medical error, majority 
is of the opinion that not many are reported or disclosed. Improving health care 
system for patient safety is need of the hour. Both management and health care 
professionals need to improve error-reporting systems in Pakistan so as to check 
the cost burden on health care.
ReseaRch on Methods – cost Methods
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Objectives: Although a number of studies have been conducted to estimate the 
economic implications of comorbid obesity in diabetic patients, mixed conclu-
(Mini-Mental State Examination [MMSE]) is equivocal in literature. To examine the 
association between them, we use longitudinal data on MMSE and CESD and causal 
inference to illustrate the relationship between two health outcomes. MethOds: 
Data were obtained from the Hispanic Established Populations for Epidemiologic 
Studies of the Elderly. Participants included 3050 noninstitutionalized Mexican 
Americans aged 65 and older followed from 1993-2001. Cognitive function and 
depressive symptoms were assessed using the MMSE and CESD at baseline and at 
2, 5, and 7 years of follow-up. Independent variables were sociodemographics, CESD, 
medical conditions. Marginal structural causal models were employed to evaluate 
the extent to which cognitive function depend not only on depressive symptoms 
measured at a single point in time but also on an individual’s entire depressive 
symptoms history. Results: our results indicate that if intervention to reduce 1 
points of depressive symptoms were made at two years prior to assessing cognitive 
function, they would result in average improvement in cognitive function of 0.11, 
95% CI [0.05, 0.16],P< .0001. cOnclusiOns: The results suggest that health inter-
vention of depressive symptoms would be useful in prevention of cognitive impair.
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Methods foR evaluating the effect Modification in the 
oBseRvational studies: a RetRosPective analysis on the iMPact 
of siMvastatina and ezetiMiBe and statins on acute MyocaRdial 
infaRction
Voci C.
Agenzia Sanitaria e Sociale Emilia-Romagna, Bologna, Italy
Objectives: Fundamental potential weaknesses of observational studies are:bias 
and effect modification. In this situation, computing an overall estimate of asso-
ciation is misleading. The aim was to compare a traditional multivariable-adjusted 
model with a propensity score (PS) model and a cluster analysis (CA) model, in esti-
mating the association between type of lipid modifying agent and hospitalization 
for Acute Myocardial Infarction (AMI). MethOds: The Health Register of Emilia-
Romagna (Italy; more than 10 Million records; 4.4 Milion Inhabitants) was used to 
select between January 1st, 2006 and December 31st, 2011 Statins and Simvastatin 
and Ezetimibe (SE) naïve users. A PS was constructed, predicting treatment assign-
ment from age, gender, use of diabetic agents, different pharmacologic agents, 
comorbidity level and utilization of outpatient services. For analysis’ purpose, the 
effect of the treatment on the risk of IMA was measured by estimates of hazard 
rations (HR) in different fashions using: multivariable Cox regression model (CRM), 
CRM adjusted for the PS, CRM model within each cluster identified by a K-means 
method. Results: Over 2,6 Mil inhabitants (+40 years) 57,902 (92.2%) patients were 
naïve statin users and 4,904 (7.8%) were SE users. Compared with Statins, the risk of 
IMA for SE resulted similar in the adjusted CRM and in the propensity CRM (HR= 1.47 
and HR= 1.49 respectively). While the CRMs performed within each cluster yielded 
different treatment effect estimates (HR= 2.39 for Cluster 1; HR= 1.36 for Cluster 2; 
1.37 for Cluster 3). cOnclusiOns: The CA allowed to identify specific subgroups 
of patients, with homogeneous risk features. The CRM within each cluster yielded 
different treatment effect estimates that might suggest the presence of unmeasured 
confounding. In that case, traditional regression model and PS developed using 
administrative data do not necessarily balance patient characteristics contained 
in clinical data. Choice among different approaches for investigating effect modi-
fication should be sensitive to the circumstances of the data analysis in applying 
observational studies.
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Objectives: Diagnosis, treatment, and management decisions in oncology can 
be particularly difficult, involving a complex web of diagnostic and therapeutic 
uncertainties, patients’ preferences and value, as well as costs. These decisions 
involve trade-offs between possible benefits and harms. There is growing interest 
in the development and application of alternative decision-making frameworks 
within oncology, including multi-criteria decision analysis (MCDA). Even though 
the literature includes several reviews on MCDA methods, applications of MCDA 
in oncology are lacking. This study sought to discuss the rationale for using MCDA 
in oncology. In this context, the following research question emerged: How can 
MCDA be used to develop a clinical decision support tool in oncology? MethOds: 
This study surveyed several applications of MCDA in the field of oncology. In par-
ticular, the study reviewed key contributions addressing screening and treatment 
decision-making in this area. It proposed research opportunities in the context 
of oncology, and presented a hypothetical scenario to show how MCDA could be 
applied in oncology. Results: The literature review identified eight studies. Five 
studies examined decision making for cancer screening. Four studies demonstrated 
applicability and acceptability of the Analytic Hierarchy Process (AHP) as a means to 
involve patients in oncology decisions and translate evidence into clinical practice. 
The study showed that a wide range of MCDA methods exist; each has its strengths 
and weaknesses. Choosing the appropriate method vary depending on the source 
and nature of information used to inform decision-making. cOnclusiOns: Given 
recent policy movements toward evidence-based decisions, multidisciplinary teams, 
and shared decision-making, the field of oncology will continuously seek ways to 
make comprehensive and transparent decisions. MCDA appears to be a promising 
tool to assist clinical decision-making in oncology and help assess trade-offs regard-
ing preferences. Nonetheless, field-testing is desirable before MCDA becomes an 
established decision-making tool in oncology.
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1First Databank, South San Francisco, CA, USA, 2First Databank
Objectives: Analyses of drug cost-effectiveness have traditionally been based 
on two key components: effectiveness measured by clinical endpoints reported 
in product label or biomedical literature, and cost obtained from available pricing 
sources. While the former is a relatively well-defined value derived from pivotal 
trials and subsequent studies, the latter has often not been well-described or rigor-
ously assessed, and may be based upon manufacturer-reported pricing information 
that has been shown to be inaccurate and unreliable. This study examines existing 
benchmarks against newly available sources of pharmaceutical pricing, describes 
their interrelationships and assesses their stability over time. MethOds: Using 
publicly available cost data for wholesale acquisition cost (WAC), average manu-
facturer price (AMP), national average drug acquisition cost (NADAC), AMP-based 
federal upper limit (FUL), and a composite of six states’ average acquisition cost 
(AAC), mean, median, and standard deviation values were calculated for a broad 
range of pharmaceuticals and trade classes (brand vs. generic) and analyzed tem-
porally for trend and consistency patterns. Results: Available pricing data reflects 
an extremely high degree of variability and inconsistent relationships, both between 
equivalent products and from one price type to another. Generic drug prices demon-
strated the greatest irregularity, and although the ratio of NADAC or AMP to WAC for 
branded drugs showed correlations overall, for given products those relationships 
could be substantially at variance. cOnclusiOns: Continuing review and analysis 
of all available price types is needed to identify a reliable drug pricing benchmark 
that permits reviewers and clinicians to determine the optimal course of treatment. 
Since reported ratios may shift over time, future reports of cost-effectiveness must 
explicitly identify the cost basis employed and its reliability for the products at issue.
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Objectives: Head-to-head randomized controlled trials (RCTs) remain the gold 
standard for establishing relative treatment efficacy and for use in cost-effective-
ness (CE) models. However, in some cases, such as rare diseases, only single-arm 
trials may be available. We identified health technology appraisals (HTAs) published 
by the National Institute for Health and Care Excellence (NICE) that included evi-
dence from single-arm trials and reviewed the use of the single-arm trial data in 
accompanying CE models. MethOds: We searched the NICE website for published 
technology appraisals using the term “single-arm”. We reviewed HTAs in which 
single-arm trials were used and recorded the date of the appraisal, disease area, use 
of the single-arm trial data, the NICE recommendation, and NICE’s comments on 
the use of the single-arm trials. Results: Twenty-two HTAs included a reference 
to one or more single-arm trials. Fourteen provided the single-arm trial data only 
as supporting evidence to at least one RCT. Of the eight that used single-arm trial 
data, all also used the data in a model; four used the data as the primary evidence of 
efficacy, two used the data to extend an RCT, and two used the data for other inputs. 
Only one of the four using the data for evidence of efficacy resulted in a positive 
recommendation from NICE. In this case, evidence was from seven single arm trials; 
two manufacturer models and the assessment group model all demonstrated the 
intervention to be dominant over standard care, and several other factors may have 
contributed to a positive recommendation. In the three HTAs resulting in a negative 
recommendation, NICE expressed concerns over the efficacy data. cOnclusiOns: 
Although RCTs are preferred for relative efficacy data for use in cost-effectiveness 
analyses in NICE HTAs, there is one case of a positive NICE recommendation despite 
efficacy evidence being based on single-arm trials.
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Objectives: Efficiency may be crucial to a health technology’s value proposition. 
Measuring time endpoints prospectively is subject to variability and bias that 
makes Time and Motion (T&M) methodology complex. The aim was to investi-
gate key design characteristics of T&M studies recently presented at ISPOR con-
ferences. MethOds: A search was performed in ScienceDirect, using “time and 
motion” as key term, restricted to ‘Value in Health’ journal for the years 2008-2013 
to identify all ISPOR conference presentations during that period. Presentations 
were excluded based on the following criteria: (1) not a T&M study; (2) not present-
ing T&M results. Results: Of 116 abstracts, 29 complied with inclusion criteria; 8 
presentations could not be obtained; 7 were later excluded; 14 were retained for 
detailed assessment: 11 were observational studies, 2 reported survey data, and 1 
was a simulation study. Distribution of interventions being studied was: drug (43%), 
medical supply (29%), device (14%), and procedure (14%). 64% were conducted in 
Europe and 43% were multi-country. Primary objective of 13 studies was measuring 
process time (one only focused on cost); 57% also reported cost results. 13 studies 
measured time for tasks composing a process in a hospital setting with number 
of tasks ranging from 2 to 8; one study measured HCP workload. 85% investigated 
two processes (15% 3-4), but none were comparative studies powered to test a 
hypotheses of time differences between groups. 43% reported inferential statistics 
(e.g. covariance analyses, 95% CIs). One study applied a multilevel model to test 
centre clustering. cOnclusiOns: This T&M study review reveals a clear choice for 
descriptive non-hypotheses testing designs; some employ inferential statistics. In 
multi-centre studies, multilevel models to account for “centre clustering” are scarce. 
sions have been reached. This study sought to assess the relationship between 
Body Mass Index (BMI) and health care costs using 2006-2010 data from the Medical 
Expenditure Panel Survey (MEPS). MethOds: Eligible patients were ≥ 18 years, with 
a diabetes diagnosis (CCC-250) and on at least one oral antidiabetic medication. 
Primary outcomes were: 1) diabetes-related direct medical costs, 2) all-cause direct 
medical costs, and 3) indirect costs. Costs were inflated to 2010 US dollars using the 
medical consumer price index. The main independent variable was BMI, categorized 
as normal weight BMI: 18.0-24.9; overweight BMI: 25.0-29.9; obese BMI: 30.0-40.0; 
and morbidly obese BMI: > 40.0 kg/m2. Covariates included demographic and clinical 
variables. Generalized linear models with gamma distribution and log link function 
were conducted. Results: A final unweighted sample size of 7,003 patients was 
obtained (14.6 million weighted), with a mean age (±SE) = 61.2 (±0.2) years, mean BMI 
(±SE) = 32.2 (±0.1), and 50.4% were males. After controlling for covariates, diabetes-
related direct medical costs of normal-weight patients ($1,622) were lower than their 
overweight ($1,955; p= 0.031), obese ($2,259; p= 0.001) and morbidly obese ($2,636; 
p= 0.003) peers. But direct all-cause medical costs of overweight patients were less 
($9,715; p= 0.021) compared to normal weight ($11,623) patients. All-cause direct 
costs for obese ($11,419) and morbidly obese ($13,043) patients were not statisti-
cally different than costs for normal weight peers. Indirect costs (estimated as lost 
productivity) were similar between all 4 cohorts ($532-$535). cOnclusiOns: Being 
overweight (BMI = 25.0 to 29.9 kg/m2) was associated with higher diabetes-related 
direct medical costs, but lower all-cause direct medical costs compared to their 
normal weight peers.
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Objectives: The aim of the study is to assess the long-term economic value of one 
additional child born in Hungary, Italy, Spain, Sweden and the UK. MethOds: Two 
different methodologies are applied. The Human Capital Approach representing 
the perspective of the society is used to estimate the potential loss in production 
for every unborn child. It is calculated by summing up the discounted value of 
all expected future gross earnings of the individual, including an imputed value 
for household production. The Lifetime Investment Approach representing the 
point of view of the government is used to calculate the impact of an additional 
child on the fiscal balance. Expected revenues from taxes and social contributions 
and expected public expenditures (e.g. education, health, pension, etc.) for the 
lifetime of average person are calculated. The net balance is discounted to obtain 
the present value. Input data is obtained from the statistical databases of the 
OECD and EUROSTAT and from own calculations. Results are presented as a per-
centage of GDP per capita for 2012. Results: Preliminary results indicate that 
there is great heterogeneity between countries in the values of one additional 
child born. The present value of future earnings according to the Human Capital 
Approach indicates that a child will produce 11 to 21 times the 2012 GDP per 
capita during his lifetime. According to the Lifetime Investment Approach, an 
average child will contribute 3.4 and 6.0 times the GDP per capita of government 
revenues by the end of his lifetime. cOnclusiOns: The two methods used pre-
sent gains (or losses) of an additional child from the perspective of the society 
as well as from the point of view of the sustainability of public finances. Results 
vary by country. Therefore, it is essential that such calculations are performed on 
a country-by-country bases.
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Objectives: To use baseline results from a prospective observational study in 
Alzheimer’s disease (AD) to evaluate methods for dealing with missing longi-
tudinal AD cost data. MethOds: GERAS is an 18-month observational study of 
costs associated with AD. Total societal costs included patient health care costs 
(including hospitalizations, outpatient visits, and medication) and social care costs 
(including home-care and day-center sessions), and caregiver informal care costs 
(from time spend on informal care). Missing longitudinal cost data due to patient 
death/institutionalization was classified as not missing at random (NMAR). Cost 
data missing for other reasons was classified as missing at random (MAR) or 
missing completely at random (MCAR). To assess the impact of imputing missing 
longitudinal cost data, patterns of missing data during follow-up were simulated 
based on baseline GERAS data to generate 10%, 20%, 30% and 40% missing data for 
MCAR, MAR and NMAR classifications. Naïve methods (including complete case 
analysis, mean imputation and regression models), multiple imputation (MI) and 
a fixed cost were applied to each dataset and %bias assessed using (estimated-
actual)/actual cost*100. Results: Total baseline societal costs were available for 
1488 (99.4%) of enrolled patients, with a mean monthly cost of € 2101(95% CI: 
€ 1980-€ 2222). For MCAR datasets, naïve methods performed as well as MI (20% 
missing data: 0.6-10.9% bias naïve methods vs 0.2-6.1% MI). For MAR data, MI 
methods performed better (-3.2% to -14.3% bias) than naïve methods (6.6%-18.0% 
bias). All approaches were consistently poor with NMAR data (bias range -31.4% to 
-38.6%); the best performing approach was to impute a fixed value (monthly cost 
of institutionalisation) with -22.6% bias. For all approaches %bias increased with 
missing data volume. cOnclusiOns: Methods used to impute missing cost data 
in AD should be tailored depending on the type of missing data, using sensitivity 
analysis to assess the impact of any assumptions.
